Latest Articles and Analysis

Payers use prior authorization and step therapy to deny care, driving health disparities.

Q1 2023 Watch: Tennessee rejecting federal HIV funding; updates on ADAPs, Medicaid, veterans care, and harm reduction.

Nursing shortages and hospital consolidation together degrade patient care and access.

Place-based sexual health care in community venues advances HIV/HCV prevention and testing outreach.

Employers can advance health equity through inclusive benefits design and quality provider networks.

Q4 2022 Watch: HHS renewed opioid emergency; CANN launched monkeypox project; HEPLISAV-B hepatitis B vaccine covered.

Louisiana and Washington HCV subscription models save millions but fail elimination goals; cost alone isn't the barrier.

Monitoring report documents HCV treatment access challenges across ADAP, Medicaid, and VA systems.

Patients face multiple monkeypox barriers: disorganized state websites, limited vaccine access, reporting gaps.

ADAP Fireside Chat addresses counterfeit medications, 340B reform, and public health workforce sustainability.

Provider language shows negative bias toward Black patients at 2.5x rate, undermining care engagement.

Innovative HIV medications available but inaccessible: payer barriers block Cabenuva and Apretude access.

Q3 2022 review of HCV drug access across ADAPs, Medicaid, and comprehensive harm reduction programs.

Community-based low-barrier HCV treatment for PWID significantly improves liver health outcomes.

West Virginia's fragmented HIV services across four entities creates barriers; centralization needed.

PrEP access remains limited by payer practices like prior authorizations despite ACA coverage requirements.

Restrictions on abortion and transgender care represent broader attacks on medication access as human right.

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

Pharmaceutical industry changes to 340B implementation impact pricing and accessibility for covered entities.

AMA survey: 93% of providers say prior authorizations delay care with 91% reporting negative clinical impact.